Carrimycin

可利霉素

Report date: 2026/03/04 20:01:44
NME

Base Information

Drug NameCarrimycin
Drug Alias NameBiotechspiramycinisovalerylspiramycin IIIisovalerylspiramycin IIisovalerylspiramycin IBitespiramycin +[8] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > Macrolides antibiotics
Mechanisms of Action50S ribosomal subunit inhibitors
Targets50S ribosomal subunit
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Oral Squamous Cell CarcinomaSquamous Cell Carcinoma of Head and Neck +[4] 
Global Approved IndicationsBacterial Infections
Approved Indications in ChinaBacterial Infections
Original Approved Country/TerritoryMainland China
Original Approved Date2019/06/24
Country/TerritoryUnited StatesUkrainePhilippines +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBeijing Capital Sci Tech Group CorpInstitute Of Medicinal Of Biotechnology Chinese Academy Of Medical SciencesShenyang Tonglian Group Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShanghai Jiao Tong University School of MedicineShanghai Tonglian Pharmaceutical Co Ltd
Inactive CompaniesShenyang Tonglian Group Co Ltd
Active IndicationsOral Squamous Cell CarcinomaSquamous Cell Carcinoma of Head and NeckBacterial Infections
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeJ01
Related LinksN/A